ONFORMATION DISCLOSURE	ATTY, DOCKET NO.
<b>∕ €</b> TATION	4970-2
( MAY 1 2 2008 S)	APPLICANT
	BOVIN et al
(Use special sheets if necessary)	FILING DATE
TOM DEMAND	a 1 00 000¢

September 22, 2006

**U.S. PATENT DOCUMENTS** FILING DATE \*EXAMINER CLASS SUBCLASS IF APPROPRIATE INITIAL **DOCUMENT NUMBER** DATE NAME FOREIGN PATENT DOCUMENTS TRANSLATION CLASS **SUBCLASS** YES DOCUMENT DATE COUNTRY WO WO 03087346 A1 10/2003 WO WO 03/034074 A1 04/2003 WO 01/40796 A2 06/2001 wo OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Blixt, O., et al; "Printed covalent glycan array for ligand profiling of diverse glycan binding proteins"; PNAS, Vol. 101, /L.B./ No. 49, pp.l 17033-17038 (2004). Kovalenko, E.I., et al; "The Modification of Cell Surface with Lipophilic Glycoconjugates and the Interaction of /L.B./ Modified Cells with Natural Killer Cells"; Russian Journal of Bioorganic Chemistry, Vol. 30, No. 3, pp. 250-260 (2004). Ångström, Jonas, et al; "Default biosynthesis pathway for blood group-related glycolipids in human small intestine as /L.B./ defined by structural identification of linear and branched glycosylceramides in a group O Le(a-b-) nonsecretor"; Glycobiology, Vol. 14, No. 1, pp. 1-12 (2004). Duk, Maria, et al; "Specificity of human anti-NOR antibodies, a distinct species of "natural" anti-α-galactosyl /L.B./ antibodies"; Glycobiology, Vol. 13, No. 4, pp. 279-284 (2003). Paulson, James C., et al; "Sialyltransferases as targets for development of immuno-suppressants"; Abstracts of Papers, 223<sup>rd</sup> ACS National Meeting, Orlando, FL, United States, April 7-11, 2002 (2002), CaRB-095 Publisher: American /L.B./ Chemical Society, Washington, DC. Krasilshchikova, M.S., et al; "Macrophage-Tumor Cell Interaction in Byrb Mouse Leukosis Model"; Baltic J. Lab. /L.B./ Animal. Sci.; Vol. 12; pp. 68-73 (2002). Kovalenko, E.I., et al; "The Incorporation of Neoglycolipids into K562 Cells: A Model for the Study of Carbohydrate-Dependent Cytolysis of Target Cells by Natural Killer Cells"; Bioorgancheskaya Khimiya; Vol. 24, No. 3, pp. 224-228 /L.B./ 1998). Henry, Stephen, et al; "Structural and immunochemical identification of Le<sup>a</sup>, Le<sup>b</sup>, H type 1, and related glycolipids in /L.B./ small intestinal mucosa of a group O Le(a b) nonsecretor"; Glycoconjugate Journal, Vol. 14; pp. 209-223 (1997). Henry, Stephen., et al; "Lewis Histo-Blood Group System and Associated Secretory Phenotypes"; Vox Sanguinis, Vol. /L.B./ 69, No. 3, pp. 166-182 (1995). Henry, Stephen M., et al; "Structural and immunochemical identification of Leb glycol-lipids in the plasma of a group O /L.B./ Le(a-b-) secretor"; Glycoconjugate Journal, Vol. 12, pp. 309-317 (1995). Henry, Stephen M., et al; "Immunochemical and immunohistological expression of Lewis histo-blood group antigens in /L.B./ small intestine including individuals of the Le(a+b+) and Le(a-b-) nonsecretor phenotypes"; Glycoconjugate Journal, Vol. 11; pp. 600-607 (1994). Henry, Stephen M., et al; "Expression of Lewis histo-blood group glycolipids in the plasma of individuals of Le(a+b+) /L.B./ and partial secretor phenotypes"; Glycoconjugate Journal, Vol. 11; pp. 593-599 (1994). Bovin, Nicolai V., et al; "Synthesis of polymeric neoglycoconjugates based on N-substituted polyacrylamides"; /L.B./ Glycoconjugate Journal.; Vol. 10, pp. 142-151 (1993). Vodovozova, E.L., et al; "Antitumour activity of cytotoxic liposomes equipped with selectin ligand SiaLex, in a mouse /L.B./

SERIAL NO.

GROUP

1623

10/593,829

*Examiner	/Layla Bland/	Date Considered	02/13/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial a this form with next communication to application.				

mammary adenocarcinoma model"; European Journal of Cancer; Vol. 36, pp. 942-949 (2000).